Obinutuzumab as a Rescue Therapy for Rituximab-Refractory NELL-1-Positive Membranous Nephropathy After Allogeneic Stem-Cell Transplantation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0752; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Our case demonstrates that rituximab failure may be driven by inadequate B-cell depletion, and that obinutuzumab, a type II anti-CD20 antibody with superior B-cell cytotoxicity, can achieve meaningful clinical response in this setting. This shows obinutuzumab as an effective rescue therapy in rituximab-refractory NELL1-positive MN and highlights the need for prospective studies to define optimal B-cell targeting strategies in the post-transplant setting."
Bone Marrow Transplantation • Glomerulonephritis • Graft versus Host Disease • Immunology • Nephrology • Renal Disease • Transplantation • NELL1
|